The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
每日生物技术脉搏：CHMP支持阿斯利康的乳腺癌疗法，益普森收购Epizyme，美国食品药品管理局持有Nuvation Bio，安斯泰来研究
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去 24 小时内生物技术领域的主要进展摘要：
Stocks In Focus
焦点股票
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
EMA的咨询委员会支持批准阿斯利康的靶向乳腺癌疗法
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Enhertu (trastuzumab deruxtecan) and Lynparza (olaparib) for breast cancer settings.
欧洲药品管理局人用药品委员会（CHMP）已建议批准Enhertu（曲妥珠单抗 deruxtecan）和Lynparza（olaparib）用于乳腺癌治疗。
Enhertu is being jointly developed and commercialized by AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo (OTC:DSNKY).
Enhertu 由以下机构共同开发和商业化阿斯利康有限公司（纳斯达克股票代码：AZN）和第一三共产株式会社（OTC: DSNKY）。
Lynparza is jointly developed and commercialized by AstraZeneca and Merck & Co Inc (NYSE:MRK).
Lynparza 由阿斯利康和默克公司（纽约证券交易所：MRK）。
Ipsen Buys Epizyme To Bolster Cancer Portfolio
益普森收购Epizyme以加强癌症投资组合
Ipsen...
I...
登录免费看全文
登录/注册